Study population and recruitment
CRPC, oligometastatic CRPC
DISEASE PROGRESSION, BONE METASTASES, DISEASE, METASTASES, PROSTATE CANCER
In accordance with the inclusion and exclusion criteria, we will enroll patients with oligometastatic CRPC whose bone metastases are localized at one to three sites as seen on WB-DWI. In addition to genuine oligometastatic CRPC patients without a history of polymetastatic disease, induced oligometastatic CRPC patients with a history of polymetastatic disease are also eligible for this trial as long as they currently have a limited number of active lesions due to previous treatments. The number of metastases and their locations in each patient are assessed through WB-DWI when disease progression is suspected before a new line of anticancer therapy is started. Systemic therapy for prostate cancer, including ARAT and chemotherapy, is prohibited during the study period except for ADT, which will be continued for the duration of the study. The physician in charge obtained informed consent and written consent forms from patients prior to study enrollment. The consent form and explanatory document included additional consent provisions for the collection and use of participant data in ancillary studies. The consent forms and explanatory documents given to the participants are shown in the Additional file 